IVIG Access Issues Highlighted In Effort To Eliminate Specialty Drug Tiers
Executive Summary
Continued problems with patient access to intravenous immune globulin therapies is helping patient advocacy groups put the spotlight on payers' handling of IVIG on their formularies and make a push for eliminating the use of specialty drug tiers
You may also be interested in...
Industry Pressures CMS To Hold ASP Plus 6 Percent Rate For Hospital Outpatient Drugs
CMS' proposal to bring the reimbursement rate for Medicare Part B drugs administered in hospital outpatient departments back to average sales price plus 6% for the first time since 2007 has resulted in a fresh wave of pressure from industry groups to keep it at that level.
Industry Pressures CMS To Hold ASP Plus 6 Percent Rate For Hospital Outpatient Drugs
CMS' proposal to bring the reimbursement rate for Medicare Part B drugs administered in hospital outpatient departments back to average sales price plus 6% for the first time since 2007 has resulted in a fresh wave of pressure from industry groups to keep it at that level.
FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns
The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger